BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025The Company continues its progression towards a Nasdaq uplisting
POMPANO BEACH, Fla., March 30, 2026 (GLOBE NEWSWIRE) — BioStem Technologies, Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today…
